NASDAQ:NKTR - Nektar Therapeutics Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $32.02 +0.68 (+2.17 %) (As of 05/19/2019 10:23 AM ET)Previous Close$32.02Today's Range$30.92 - $32.3652-Week Range$29.22 - $92.17Volume1.71 million shsAverage Volume1.65 million shsMarket Capitalization$5.58 billionP/E Ratio8.47Dividend YieldN/ABeta2.96 ProfileAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Nektar Therapeutics, a biopharmaceutical company, develops drug candidates for cancer, auto-immune disease, and chronic pain in the United States. The company develops NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; and NKTR-214, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in Phase I to treat immuno-oncology. It also develops NKTR-358, cytokine Treg stimulant, which is in Phase I to treat autoimmune diseases; NKTR-262, a toll-like receptor agonist that is in Phase I for solid tumors; and NKTR-255, which is in preclinical stage for immuno-oncology. In addition, the is developing ADYNOVATE and ADYNOVI for hemophilia A; MOVANTIK for opioid-induced constipation in adult patients with chronic non-cancer pain, and who have an inadequate response to laxatives; CIMZIA for crohn's disease, rheumatoid arthritis, and psoriasis/ankylosing spondylitis; and MIRCERA for anemia associated with chronic kidney disease. Further, it is developing Macugen for age-related macular degeneration; Somavert for acromegaly; Neulasta for neutropenia; Dapirolizumab Pegol for systemic lupus erythematosus; PEGPH20 for pancreatic, non-small cell lung cancer, and other tumor types; and longer-acting blood clotting proteins for hemophilia. The company has collaboration agreement with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Halozyme Therapeutics, Inc.; Bristol-Myers Squibb Company; Baxalta Incorporated; and Eli Lilly and Company, as well as with Merck KGaA and Pfizer Inc to develop a therapy for treating pancreatic cancer. Nektar Therapeutics was founded in 1990 and is headquartered in San Francisco, California. Receive NKTR News and Ratings via Email Sign-up to receive the latest news and ratings for NKTR and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals SectorMedical Current SymbolNASDAQ:NKTR Previous Symbol CUSIP64026810 CIK906709 Webwww.nektar.com Phone415-482-5300Debt Debt-to-Equity Ratio0.21 Current Ratio14.94 Quick Ratio14.83Price-To-Earnings Trailing P/E Ratio8.47 Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$1.19 billion Price / Sales4.68 Cash Flow$3.9975 per share Price / Cash Flow8.01 Book Value$9.37 per share Price / Book3.42Profitability EPS (Most Recent Fiscal Year)$3.78 Net Income$681.31 million Net Margins55.65% Return on Equity37.63% Return on Assets29.67%Miscellaneous Employees618 Outstanding Shares174,310,000Market Cap$5.58 billion Next Earnings Date8/14/2019 (Estimated) OptionableOptionable Nektar Therapeutics (NASDAQ:NKTR) Frequently Asked Questions What is Nektar Therapeutics' stock symbol? Nektar Therapeutics trades on the NASDAQ under the ticker symbol "NKTR." How were Nektar Therapeutics' earnings last quarter? Nektar Therapeutics (NASDAQ:NKTR) announced its earnings results on Wednesday, May, 8th. The biopharmaceutical company reported ($0.68) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.71) by $0.03. The biopharmaceutical company had revenue of $28.22 million for the quarter, compared to analysts' expectations of $25.45 million. Nektar Therapeutics had a return on equity of 37.63% and a net margin of 55.65%. During the same quarter in the previous year, the firm earned ($0.60) earnings per share. View Nektar Therapeutics' Earnings History. When is Nektar Therapeutics' next earnings date? Nektar Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, August 14th 2019. View Earnings Estimates for Nektar Therapeutics. What price target have analysts set for NKTR? 11 equities research analysts have issued 1-year target prices for Nektar Therapeutics' shares. Their forecasts range from $38.00 to $100.00. On average, they expect Nektar Therapeutics' stock price to reach $72.60 in the next year. This suggests a possible upside of 126.7% from the stock's current price. View Analyst Price Targets for Nektar Therapeutics. What is the consensus analysts' recommendation for Nektar Therapeutics? 11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nektar Therapeutics in the last year. There are currently 2 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Nektar Therapeutics. What are Wall Street analysts saying about Nektar Therapeutics stock? Here are some recent quotes from research analysts about Nektar Therapeutics stock: 1. According to Zacks Investment Research, "Nektar reported encouraging first-quarter results, beating estimates for both earnings and sales. The company has a promising pipeline with several candidates and regulatory updates lined up for the next several quarters. Additionally, regular partnerships have enhanced the company’s financial position. Nektar is poised to receive significant sales milestone payments plus royalties for Movantik, Adynovate and Neulasta, under license agreements with AstraZeneca, Takeda and Amgen, respectively. Also, its recent co-development deals with Lilly for NKTR-358 and Bristol-Myers for NKTR-214 are encouraging. The deals provide revenues and reduce expenses by sharing research costs. On the flip side, Nektar relies heavily on partners for revenues. Partnership-related setbacks may thus weigh heavily on the company’s results in the future. Shares of the company have underperformed the industry so far this year." (5/14/2019) 2. HC Wainwright analysts commented, "Our 12-month, $47 price target on shares of Nektar is based on a 13-year DCF-driven, sum-of-the-parts analysis. Our DCF is driven by beta of 1.24, terminal growth rate of 0.5%, risk premium of 4.93%, calculated WACC of 9.0%, and tax rate of 15% beginning in FY 2023. Cancer together represent about 71% of our target. In RCC, we assume commercial adoption in patients with PD-L1 expression at <1% (about 67% of the total clear cell RCC opportunity)."" (3/4/2019) 3. Mizuho analysts commented, "We expect these events to be important drivers for NKTR shares as we continue to believe that a majority of the company’s value lies in NKTR-214." (3/1/2019) Has Nektar Therapeutics been receiving favorable news coverage? News headlines about NKTR stock have been trending positive this week, InfoTrie reports. InfoTrie identifies negative and positive media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Nektar Therapeutics earned a news sentiment score of 2.2 on InfoTrie's scale. They also gave news articles about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the stock's share price in the immediate future. Who are some of Nektar Therapeutics' key competitors? Some companies that are related to Nektar Therapeutics include BioMarin Pharmaceutical (BMRN), GRIFOLS S A/S (GRFS), Teva Pharmaceutical Industries (TEVA), Genmab A/S (GNMSF), Mylan (MYL), Ono Pharmaceutical (OPHLF), Ionis Pharmaceuticals (IONS), Sarepta Therapeutics (SRPT), Bausch Health Companies (BHC), SAGE Therapeutics (SAGE), Jazz Pharmaceuticals (JAZZ), Beigene (BGNE), Marina Biotech (MRNA), Alnylam Pharmaceuticals (ALNY) and Loxo Oncology (LOXO). What other stocks do shareholders of Nektar Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Nektar Therapeutics investors own include Hawkins (HWKN), Micron Technology (MU), Alibaba Group (BABA), NVIDIA (NVDA), Celgene (CELG), Incyte (INCY), Puma Biotechnology (PBYI), Gilead Sciences (GILD), Netflix (NFLX) and Intel (INTC). Who are Nektar Therapeutics' key executives? Nektar Therapeutics' management team includes the folowing people: Mr. Howard W. Robin, CEO, Pres & Director (Age 66)Mr. Gil M. Labrucherie, Sr. VP & CFO (Age 47)Mr. John Nicholson, Sr. VP & COO (Age 67)Dr. Maninder Hora, Sr. VP of Pharmaceutical Devel. & Chief Technical Operations Officer (Age 65)Dr. Stephen K. Doberstein, Chief R&D Officer (Age 60) Who are Nektar Therapeutics' major shareholders? Nektar Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include FMR LLC (11.72%), Primecap Management Co. CA (11.11%), Wellington Management Group LLP (7.44%), BlackRock Inc. (7.18%), Janus Henderson Group PLC (1.41%) and Geode Capital Management LLC (1.38%). Company insiders that own Nektar Therapeutics stock include Christopher A Kuebler, Dennis L Winger, Gil M Labrucherie, Howard W Robin, Ivan P Gergel, Jeffrey Robert Ajer, Jillian B Thomsen, John Nicholson, Lutz Lingnau, Maninder Hora, R Scott Greer, Robert Chess, Roy A Whitfield and Stephen K Doberstein. View Institutional Ownership Trends for Nektar Therapeutics. Which major investors are selling Nektar Therapeutics stock? NKTR stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Morgan Stanley, BlackRock Inc., Renaissance Technologies LLC, First Trust Advisors LP, State of Wisconsin Investment Board, ArrowMark Colorado Holdings LLC and Goldman Sachs Group Inc.. Company insiders that have sold Nektar Therapeutics company stock in the last year include Dennis L Winger, Gil M Labrucherie, Howard W Robin, Jeffrey Robert Ajer, Jillian B Thomsen, John Nicholson, Maninder Hora, R Scott Greer and Stephen K Doberstein. View Insider Buying and Selling for Nektar Therapeutics. Which major investors are buying Nektar Therapeutics stock? NKTR stock was acquired by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, BlueMountain Capital Management LLC, Dimensional Fund Advisors LP, Rhenman & Partners Asset Management AB, Geode Capital Management LLC, AQR Capital Management LLC, SG Americas Securities LLC and Wells Fargo & Company MN. View Insider Buying and Selling for Nektar Therapeutics. How do I buy shares of Nektar Therapeutics? Shares of NKTR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Nektar Therapeutics' stock price today? One share of NKTR stock can currently be purchased for approximately $32.02. How big of a company is Nektar Therapeutics? Nektar Therapeutics has a market capitalization of $5.58 billion and generates $1.19 billion in revenue each year. The biopharmaceutical company earns $681.31 million in net income (profit) each year or $3.78 on an earnings per share basis. Nektar Therapeutics employs 618 workers across the globe. What is Nektar Therapeutics' official website? The official website for Nektar Therapeutics is http://www.nektar.com. How can I contact Nektar Therapeutics? Nektar Therapeutics' mailing address is 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO CA, 94158. The biopharmaceutical company can be reached via phone at 415-482-5300 or via email at [email protected] MarketBeat Community Rating for Nektar Therapeutics (NASDAQ NKTR)Community Ranking: 3.2 out of 5 ( )Outperform Votes: 513 (Vote Outperform)Underperform Votes: 297 (Vote Underperform)Total Votes: 810MarketBeat's community ratings are surveys of what our community members think about Nektar Therapeutics and other stocks. Vote "Outperform" if you believe NKTR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NKTR will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/19/2019 by MarketBeat.com StaffFeatured Article: Earnings Per Share Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.